India is one of the fastest-growing pharma markets globally, with an aging population, an increase in lifestyle diseases, and rising consumer demand for healthcare. At the same time, large gaps in early diagnosis, long-term disease management, and access to affordable quality treatment continue to put pressure on India’s healthcare system, intensifying the need for timely and scalable solutions. This urgent need has led businesses to strategize localized innovation and develop holistic care.
Our India Region Formulations (IRF) business is at the forefront of this healthcare revolution and continues to outperform the market, driven by strong performance across our top four therapies, namely, cardiac, respiratory, anti-diabetic, and gastrointestinal.
8th largest company in the Indian Pharmaceutical Market (IPM)
5 Lupin brands ranked in top 300 IPM brands
#1 in anti-TB, #2 in respiratory segment, #3 in both anti-diabetes and cardiology
5 flagship brands - Gluconorm-G, Budamate, Huminsulin, Ivabrad, and Rablet ranked in the top 300 IPM
19 brands featured in Top 500 IPM
Supported by 250,000 HCPs across India
Lupin’s IRF business delivers a strong portfolio of generics with leading therapies across diabetes, cardiology, gastroenterology and more, improving affordability and everyday access to care.
In the biosimilars segment, Etanercept is Lupin’s flagship injectable biologic for chronic immune-mediated inflammatory diseases, including rheumatoid arthritis, psoriatic arthritis, axial spondyloarthritis, and plaque psoriasis, addressing significant unmet patient needs. These capabilities are anchored in Lupin Biotech, our dedicated research and state-of-the-art manufacturing platform focused on developing high-quality biosimilars at scale.
Complementing this, Lupin continues to expand its footprint in complex specialty drugs, including inhalation therapies and innovative combinations, strengthening long-term, patient-centric healthcare solutions.
Anya is India’s first Al-powered, multilingual health chatbot, offering medically verified answers and a safe space for all users. Accessible 24/7 on WhatsApp, Anya chatbot responds in 20 Indian languages and delivers solutions across 17 therapy areas.
Our India business focuses on key therapy areas, aiming to deliver affordable care with quality and trusted outcomes for people.
Lupin ranks #3 in the anti-diabetic market in India and manufactures 15 of the top 20 anti-diabetic molecules in the country. Two of our key products also rank #1 and #3 in the U.S. market, underscoring global leadership. Our business also expanded this portfolio through the strategic acquisitions of Gibtulio, Ajaduo, and Huminsulin.
Beyond medicines, Lupin focuses on holistic diabetes care through initiatives such as HuMrahi, which has supported 200,000+ patients, featuring 200+ diabetes educators.
Lupin is committed to extending care beyond prescriptions through patient-centric programs that empower individuals and improve health outcomes. From setting up 10,000+ health camps to battle diabetes and cardiac conditions to India's 1st digital asthma educator platform, our deep patient engagement and purpose-driven innovation are bringing us one step closer to a healthier world.
